| Primary information |
|---|
| ID | antitb_1217 |
| Peptide Name | Lassomycin |
| Sequence | GLRRLFADQLVGRRNI-CO2CH3 |
| N-terminal Modification | Involved in Cyclic formation |
| C-terminal Modification | Addition of Methyl ester |
| Chemical Modification | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Linear/ Cyclic | Cyclic |
| Length | 16 |
| Chirality | L |
| Nature | Highly Basic |
| Source | Natural |
| Origin | Extracts from soil actinomycetes |
| Species | Mycobacterium avium |
| Strain | Mycobacterium avium subsp. Paratuberculosis |
| Inhibition Concentartion | MIC = 0.125-0.25 μg/ml or 0.07-0.13 μM |
| In vitro/In vivo | In vitro |
| Cell Line | Human NIH 3T3 and HepG2, erythrocytes |
| Inhibition Concentartion | NA |
| Cytotoxicity | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| In vivo Model | None |
| Lethal Dose | NA |
| Immune Response | NA |
| Mechanism of Action | Uncoupling ATPase from proteolytic activity |
| Target | ClpC1 ATPase complex |
| Combination Therapy | None |
| Other Activities | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Pubmed ID | 24684906 |
| Year of Publication | 2014 |
| 3-D Structure | NA |